| Monday | ||||
Resolution Bioscience… Resolution Bioscience announced an agreement with LabCorp to make the Resolution ctDx Lung assay available to clinicians and patients. The fast, accurate, and non-invasive test is designed to detect actionable mutations in non-small cell lung cancer, or NSCLC, genes recommended by professional guidelines. The assay will be performed in Resolution's CLIA laboratory as a laboratory developed test, and is expected to be available exclusively from LabCorp in the first half of 2020. The clinical utility of the Resolution ctDx Lung assay has been successfully demonstrated in multiple clinical studies with leading cancer centers and academic research institutions, including Memorial Sloan Kettering Cancer Center, Northern Cancer Institute of Sydney, Dana-Farber Cancer Institute, and Vanderbilt University. | ||||
Interpace Biosciences… Interpace Biosciences (IDXG) announced that its agreement with LabCorp (LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered in to their collaboration in 2016 through which LabCorp became the first national laboratory in the U.S. to offer electronic ordering and result reporting for Interpace's proprietary ThyGeNEXT and ThyraMIR tests for thyroid cancer. Terms of the agreement extension were not disclosed. | ||||
Meeting to be held in New… Meeting to be held in New York on February 24 hosted by Mizuho. | ||||
| Thursday | ||||
Meeting to be held in New… Meeting to be held in New York on February 24 hosted by Mizuho. | ||||
| Over a week ago | ||||
Piper Sandler analyst… Piper Sandler analyst William Quirk raised his price target for LabCorp to $219 from $177 saying the company reported "solid" results in spite of its leadership transition. The first quarter under the new CEO went smoothly, says the analyst, who notes that if the situation in China were to worsen, it could have a negative impact on the Covance business. He keeps an Overweight rating on the shares. | ||||
Sees FY20 revenue growth… Sees FY20 revenue growth of 4.0%-6.0% over 2019 revenue of $11.55B, which includes the negative impact from the disposition of business of approximately 0.2% as well as the benefit from foreign currency translation of 0.4%. FY20 consensus $11.94B. 2020 Free Cash Flow guidance of $950M-$1.05B. | |
Reports Q4 revenue $3B,… Reports Q4 revenue $3B, consensus $2.93B. | |
Notable companies… Notable companies reporting before tomorrow's open, with earnings consensus, include Alibaba (BABA), consensus $2.22... PepsiCo (PEP), consensus $1.44... FIS (FIS), consensus $1.53... Duke Energy (DUK), consensus 87c... Zoetis (ZTS), consensus 88c... Waste Management (WM), consensus $1.15... AIG (AIG), consensus $1... Kraft Heinz (KHC), consensus 68c... LabCorp (LH), consensus $2.80... Incyte (INCY), consensus 57c... BorgWarner (BWA), consensus $1.02... YETI (YETI), consensus 43c. | |
Notable companies… Notable companies reporting before tomorrow's open, with earnings consensus, include Alibaba (BABA), consensus $2.22... PepsiCo (PEP), consensus $1.44... FIS (FIS), consensus $1.53... Duke Energy (DUK), consensus 87c... Zoetis (ZTS), consensus 88c... Waste Management (WM), consensus $1.15... AIG (AIG), consensus $1... Kraft Heinz (KHC), consensus 68c... LabCorp (LH), consensus $2.80... Incyte (INCY), consensus 57c... BorgWarner (BWA), consensus $1.02... YETI (YETI), consensus 43c. | |
Fluidigm (FLDM) announced… Fluidigm (FLDM) announced that Covance, the drug development business of LabCorp (LH), a leading global life sciences company, has selected Fluidigm's CyTOF technology and the industry-leading Maxpar Direct Immune Profiling Assay to develop highly multiplexed immune profiling services. Setting an industry first, high-multiplex mass cytometry enables clinical researchers to simultaneously profile more than 50 cell surface and intracellular parameters in a single run. Ideal for use with panels comprising more than 20 parameters, mass cytometry simplifies high-parameter panel design by using non-overlapping metal isotope tags that can be easily distinguished in cells using CyTOF technology. Empowering clinical researchers to deeply profile cell phenotypes and function with robust reproducibility, mass cytometry has been used in more than 70 clinical trials and is trusted by academic medical centers, pharmaceutical companies and research consortia worldwide. |